Roche reboot. Plus five updates on Trump 2.0

How the once-dominant oncology company has overhauled its strategy 

Once pharma’s oncology powerhouse, Roche (SIX:ROG; OTCQB:RHHBY) is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the Swiss pharma has reshaped its strategy for long-term growth. They also discuss another tumultuous weekend for staff at FDA and NIH, as well as the challenges of precision medicine for psychiatric conditions.